Northwest Biotherapeutics (NWBO) presents a deeply negative liquidation posture as of December 31, 2025. Total assets of $81.3 million face total liabilities of $128.9 million at face value, producing a book stockholders' deficit of $(60.3) million. Under liquidation haircuts, the picture is materially worse. Cash of $3.0 million recovers at 100% — essentially the only hard-currency asset. Current assets total $5.5 million; prepaid and other current assets of $2.2 million would recover at a substantial discount. The dominant noncurrent asset category is intangibles at $53.2 million (net), including approximately $52.0 million attributed to identifiable intangibles from the October 2025 Advent BioServices acquisition. Under the liquidation lens, intangibles receive a 0% recovery haircut, eliminating this balance entirely. PP&E net of $17.4 million (primarily Sawston, UK manufacturing facility equipment) recovers at 50–70%, or roughly $8.7–$12.2 million. ROU assets of $4.2 million are excluded as their value is offset by corresponding lease liabilities at face value. Goodwill of $0.6 million recovers at 0%. Against these haircut assets, the liability stack remains at face value: current liabilities of $91.7 million include accounts payable and accrued liabilities of $30.8 million, Level 3 fair value convertible debt (total long-term debt $60.0 million plus current notes payable $9.5 million), the Advent acquisition contingent consideration liability of $9.4 million, and other current liabilities of $8.4 million. Noncurrent liabilities of $37.2 million include $12.3 million in long-term notes payable, $4.4 million noncurrent operating lease liability, and the $13.2 million deferred tax liability arising from the Advent intangible step-up. The aggregate face-value liability stack of $128.9 million substantially exceeds any plausible liquidation asset recovery. Estimated liquidation recovery to equity is deeply negative, consistent with MFFAIS CLV/LLV/OLV of $(153) million. The Advent acquisition, closed October 24, 2025 for approximately $1.9 million in cash consideration plus assumption of net AP, added $52.0 million of intangibles (zero liquidation value), a $13.2 million deferred tax liability, $9.4 million contingent consideration, and $0.8 million incremental lease contingency — all net-negative in a liquidation scenario. The filing discloses going concern doubt, a pretax loss of $62.8 million for 2025 (vs. $83.8 million in 2024), and $828 million in U.S. NOL carryforwards fully reserved with a $297.8 million valuation allowance. Post-period financing is thin: $10.5 million raised Q1 2026 via equity and debt, with $6.3 million of new convertible notes added in January–March 2026 at 9–11% rates. The March 2026 $5 million commercial loan converting at 86% VWAP represents continuing dilutive debt reliance. Filing discusses the Advent acquisition intangibles and the resulting deferred tax liability extensively in MD&A and Note 15 but the contingent consideration balance is tagged under BusinessCombinationContingentConsiderationLiabilityCurrent rather than a separate acquisition-specific tag.
▼ Community Notes